Treatment deliverability: ARTD and ARDI
| Based on 6 cycles of ibrutinib-R-mini-CHOP . | Median ARTD % (IQR) . | Median ARDI % (IQR) . | Median ARTD % (SD) . | Median ARDI % (SD) . |
|---|---|---|---|---|
| Entire regimen | 97.3 (81.9- 99.8) | 97.2 (87.8- 99.8) | 85.7 (24.3) | 93.7 (8.5) |
| R | 100.2 (93.8- 104.2) | 99.5 (94.6- 103.5) | 90.6 (25.6) | 98.2 (9.3) |
| Chemotherapy (mini-CHOP) | 97.3 (81.9- 99.8) | 98.0 (91.6-100.6) | 85.7 (24.3) | 95.3 (7.9) |
| Cyclophosphamide + doxorubicin combined | 99.2 (83.5- 101.0) | 99.1 (94.0- 101.1) | 87.4 (24.4) | 96.1 (8.4) |
| Ibrutinib | 97.6 (62.7- 100.0) | 97.1 (78.2- 100.0) | 77.3 (33.5) | 77.7 (53.7) |
| Based on 6 cycles of ibrutinib-R-mini-CHOP . | Median ARTD % (IQR) . | Median ARDI % (IQR) . | Median ARTD % (SD) . | Median ARDI % (SD) . |
|---|---|---|---|---|
| Entire regimen | 97.3 (81.9- 99.8) | 97.2 (87.8- 99.8) | 85.7 (24.3) | 93.7 (8.5) |
| R | 100.2 (93.8- 104.2) | 99.5 (94.6- 103.5) | 90.6 (25.6) | 98.2 (9.3) |
| Chemotherapy (mini-CHOP) | 97.3 (81.9- 99.8) | 98.0 (91.6-100.6) | 85.7 (24.3) | 95.3 (7.9) |
| Cyclophosphamide + doxorubicin combined | 99.2 (83.5- 101.0) | 99.1 (94.0- 101.1) | 87.4 (24.4) | 96.1 (8.4) |
| Ibrutinib | 97.6 (62.7- 100.0) | 97.1 (78.2- 100.0) | 77.3 (33.5) | 77.7 (53.7) |
IQR, interquartile range; SD, standard deviation.